Glitazone bone-loss trigger found

The suspected link between glitazones and bone loss may be due to increased production of bone-destroying osteoclasts, studies in mice have suggested.

The findings add to fears that patients taking glitazones for type-2 diabetes could be at increased risk of osteoporosis.

Clinical trials, such as A Diabetes Outcome Progress in Trial, have already shown significant loss in bone density of patients taking glitazones.

A study carried out at the Howard Hughes Medical Institute in California, now offers a potential explanation.

It focused on peroxisome proliferator-activator receptor-gamma (PPAR-gamma), the molecular target that is activated by glitazones.

It is known to block osteoblast differentiation but its effect on osteoclasts is unknown.

Mice were genetically engineered to lack PPAR-gamma in osteoclasts. They went on to develop increased bone mass.

By contrast, when mice were given rosiglitazone, which activates PPAR-gamma, they developed osteoporosis.

The researchers argue that activating PPAR-gamma accelerates osteoclast differentiation and bone resorption.

'These findings have potential clinical implications that long-term rosiglitazone use in treatment of type-2 diabetes and insulin resistance could cause osteoporosis, owing to a combination of decreased bone formation and increased bone resorption,' the researchers commented.

Findings may also offer a novel therapeutic target for osteoporosis and even rheumatoid arthritis. Selective modulators of PPAR-gamma may be able to boost bone mass in these diseases.

rachel.liddle@haymarket.com

Comment below and tell us what you think

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register

Already registered?

Sign in

Follow Us:

Just published

GMC to restart fitness to practise cases and PLAB tests within weeks

GMC to restart fitness to practise cases and PLAB tests within weeks

Fitness to practise cases paused during the coronavirus pandemic will restart this...

NHS England confirms plan to add practice managers to £20,000 golden hello scheme

NHS England confirms plan to add practice managers to £20,000 golden hello scheme

NHS England hopes to extend the £20,000 golden hello scheme for first-time partners...

COVID-19 risk assessments could devastate fragile GP workforce in parts of England

COVID-19 risk assessments could devastate fragile GP workforce in parts of England

COVID-19 risk assessments could devastate the threadbare primary care workforce in...

GP trainees still paying thousands for NHS levy Boris Johnson promised to scrap

GP trainees still paying thousands for NHS levy Boris Johnson promised to scrap

GP trainees are among overseas NHS staff continuing to face demands for thousands...

GP fear surge of avoidable illness as patients skip routine vaccinations in pandemic

GP fear surge of avoidable illness as patients skip routine vaccinations in pandemic

Patients have been urged not to skip routine vaccination amid concerns the COVID-19...

GPs plan drive-through flu clinics amid COVID-19 safety fears

GPs plan drive-through flu clinics amid COVID-19 safety fears

GP practices are planning drive-through flu clinics to maximise uptake of jabs during...